Trial Profile
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jul 2020 Results investigating whether adavosertib had increased efficacy versus placebo when administered with standard of care chemotherapy doublet in women with known or suspected loss-of-function TP53-mutated, platinum-sensitive ovarian cancer published in the Clinical Cancer Research
- 13 Jun 2019 Trial has been completed in UK.
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.